Research Article| Volume 42, ISSUE 12, P1768-1774, August 2006

Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours



      Halofuginone (tempostatin™) is a synthetic derivative of a quinazolinone alkaloid showing anti-angiogenic, anti-metastatic and anti-proliferative effects in preclinical studies. The objectives of this phase I study were to assess the dose-limiting toxicities (DLTs), to determine the maximum tolerated dose (MTD) and to study the pharmacokinetics (PKs) of halofuginone when administered once or twice daily orally to patients with advanced solid tumours.


      Patients were treated with escalating doses of halofuginone at doses ranging from 0.5 to 3.5 mg/day. For pharmacokinetic analysis plasma sampling was performed during the first and second course and assayed using a validated high-performance liquid chromatographic assay with mass spectrometric detection.


      Twenty-four patients received a total of 106 courses. The ‘acute’ MTD was reached at 3.5 mg/day, with nausea, vomiting, and fatigue as DLT. The recommended dose for chronic administration was defined as 0.5 mg/day with the requirement of 5HT3 antagonists to control nausea and vomiting considered as DLT. Several patients experienced bleeding complications on treatment with halofuginone in which a causal relationship could not be excluded. The PKs of halofuginone were linear over the dose range studied with a large interpatient variability.


      In this study the DLT of halofuginone was nausea, vomiting, and fatigue. The recommended dose for phase II studies of halofuginone is 0.5 mg administered orally, once daily.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ramirez F.
        • Rifkin D.B.
        Cell signaling events: a view from the matrix.
        Matrix Biol. 2003; 22: 101-107
        • Folz S.D.
        • Lee B.L.
        • Nowakowski L.H.
        • Conder G.A.
        Anticoccidial evaluation of halofuginone, lasalocid, maduramicin, monensin and salinomycin.
        Vet Parasitol. 1988; 28: 1-9
        • Halevy O.
        • Nagler A.
        • Levi-Schaffer F.
        • Genina O.
        • Pines M.
        Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
        Biochem Pharmacol. 1996; 52: 1057-1063
        • Granot I.
        • Halevy O.
        • Hurwitz S.
        • Pines M.
        Halofuginone: an inhibitor of collagen type I synthesis.
        Biochim Biophys Acta. 1993; 1156: 107-112
        • Pines M.
        • Knopov V.
        • Genina O.
        • Lavelin I.
        • Nagler A.
        Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
        J Hepatol. 1997; 27: 391-398
        • Pines M.
        • Nagler A.
        Halofuginone: a novel antifibrotic therapy.
        Gen Pharmacol. 1998; 30: 445-450
        • Elkin M.
        • Miao H.-Q.
        • Nagler A.
        • et al.
        Halofuginone: a potent inhibitor of critical steps in angiogenesis progression.
        FASEB J. 2000; 14: 2477-2485
        • McGaha T.L.
        • Phelps R.G.
        • Spiera H.
        • Bona C.
        Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts.
        J Invest Dermatol. 2002; 118: 461-470
        • Nagler A.
        • Miao H.Q.
        • Aingorn H.
        • et al.
        Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone.
        Arterioscler Thromb Vasc Biol. 1997; 17: 194-202
        • Elkin M.
        • Reich R.
        • Nagler A.
        • et al.
        Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
        Clin Cancer Res. 1999; 5: 1982-1988
        • Elkin M.
        • Ariel I.
        • Miao H.-Q.
        • et al.
        Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
        Cancer Res. 1999; 59: 4111-4118
        • Abramovitch R.
        • Itzik A.
        • Harel H.
        • Nagler A.
        • Vlodavsky I.
        • Siegal T.
        Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model – an MRI study.
        Neoplasia. 2004; 6: 480-489
        • Nagler A.
        • Ohana M.
        • Shibolet O.
        • et al.
        Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone.
        Eur J Cancer. 2004; 40: 1397-1403
        • Gross D.J.
        • Reibstein I.
        • Weiss L.
        • et al.
        Treatment with halofuginone results in marked growth inhibition of a von Hippel–Lindau pheochromocytoma in vivo.
        Clin Cancer Res. 2003; 9: 3788-3793
        • Gavish Z.
        • Pinthus J.H.
        • Barak V.
        • et al.
        Growth inhibition of prostate cancer xenografts by halofuginone.
        Prostate. 2002; 51: 73-83
        • Stecklair K.P.
        • Hamburger D.R.
        • Egorin M.J.
        • Parise R.A.
        • Covey J.M.
        • Eiseman J.L.
        Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and fisher 344 rats.
        Cancer Chemother Pharmacol. 2001; 48: 375-382
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • et al.
        New guidelines to evaluate the response to treatment of solid tumours.
        J Natl Cancer Instit. 2000; 92: 205-216
        • Mick R.
        • Crowley J.
        • Carroll R.
        • et al.
        Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.
        Contr Clin Trials. 2000; 21: 343-359